Through a combination of our internal efforts and aggressive in-licensing, Archemix has consolidated the leading worldwide intellectual property position for aptamer therapeutics. We own or have licensed exclusive rights to over 200 issued patents and approximately 250 pending patent applications pertaining to the discovery and development of aptamers and their role in treating disease. ISIS Pharmaceuticals granted Archemix an exclusive license to chemistry patent rights to discover, develop and commercialize products containing aptamers. In addition, SomaLogic granted Archemix non-exclusive rights to their own and licensed intellectual property for the development and commercialization of aptamer therapeutics and specified nontherapeutic applications of aptamers including target validation. We actively seek to protect our proprietary technology that we consider important to aptamer therapeutics in the United States and other key pharmaceutical and pharmaceutical manufacturing markets. In this regard, we have focused on patents, patent applications and other intellectual property covering:
|
|
